Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon gamma-1b + adefovir dipivoxil
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This is a combination of two drugs, interferon gamma-1b and adefovir dipivoxil. Interferon gamma-1b is a recombinant form of human interferon-gamma, used primarily to reduce the frequency and severity of serious infections in chronic granulomatous disease and to slow progression in severe malignant osteopetrosis. It acts as an immunomodulatory cytokine by binding to the type II interferon receptor (IFNGR1), activating JAK1/JAK2 kinases, leading to STAT1 phosphorylation and transcriptional activation of immune-related genes[6][4][7]. Adefovir dipivoxil is an oral nucleotide analog reverse transcriptase inhibitor (ntRTI) indicated for the treatment of chronic hepatitis B. It is converted intracellularly into its active metabolite, which inhibits HBV DNA polymerase by competing with deoxyadenosine triphosphate and causing DNA chain termination[5][2]. The combination has been studied for potential synergistic antiviral effects in chronic hepatitis B infection[1].
- Other names
- bis-POM PMEA (for adefovir dipivoxil)
02
Targets
POLA1 (DNA polymerase alpha)HBV Pol (Hepatitis B virus polymerase)IFNGR1 (Interferon gamma receptor 1)POLG (Mitochondrial DNA polymerase gamma)
Beyond the preview
Go deeper on interferon gamma-1b + adefovir dipivoxil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon gamma-1b + adefovir dipivoxil.